A UK-based KOL describes the current landscape for patients with bladder cancer, as well as challenges to the adoption of therapies and NICE reimbursement issues. The clinical development of pipeline therapies and current unmet needs in bladder cancer are also discussed.

This interview was conducted on Jan. 27, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.  

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.